Alimentary Pharmacology & Therapeutics

Barrett's oesophagus, dysplasia and pharmacologic acid suppression
pp. 269-276(8)
Authors: Fitzgerald, R. C.; Lascar, R.; Triadafilopoulos, G.

Tegaserod
pp. 277-289(13)
Author: Camilleri, M.

A drug therapy for the prevention of variceal haemorrhage
pp. 291-310(20)
Authors: Tripathi, D.; Hayes, P. C.

The potential role for photodynamic therapy in the management of upper gastrointestinal disease
pp. 311-321(11)
Authors: Barr, H.; Dix, A. J.; Kendall, C.; Stone, N.

The prevention of colorectal cancer
pp. 323-336(14)
Authors: Dove-Edwin, I.; Thomas, H. J. W.

Mycobacterium avium subsp. paratuberculosis as one cause of Crohn's disease
pp. 337-346(10)
Authors: Chamberlin, W.; Graham, D. Y.; Hulten, K.; El-Zimaity, H. M. T.; Schwartz, M. R.; Naser, S.; Shafran, I.; El-Zaatari, F. A. K.

Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of `on-demand' therapy for 6 months
pp. 347-354(8)
Authors: Talley, N. J.; Lauritsen, K.; Tunturi-Hihnala, H.; Lind, T.; Moum, B.; Bang, C.; Schulz, T.; Omland, T. M.; Delle, M.; Junghard, O.

Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome
pp. 355-361(7)
Authors: Poynard, T.; Regimbeau, C.; Benhamou, Y.

Minimal renal dysfunction in inflammatory bowel disease is related to disease activity but not to 5-ASA use
pp. 363-369(7)
Authors: Herrlinger, K. R.; Noftz, M. K.; Fellermann, K.; Schmidt, K.; Steinhoff, J.; Stange, E. F.

Oral tacrolimus long-term therapy in patients with Crohn's disease and steroid resistance
pp. 371-377(7)
Authors: Ierardi, E.; Principi, M.; Francavilla, R.; Pisani, A.; Rendina, M.; Ingrosso, M.; Guglielmi, F. W.; Panella, C.; Francavilla, A.

Non-Helicobacter pylori bacterial flora during acid-suppressive therapy: differential findings in gastric juice and gastric mucosa
pp. 379-388(10)
Authors: Sanduleanu, S.; Jonkers, D.; De Bruine, A.; Hameeteman, W.; Stockbrügger, R. W.

Evaluation of a novel continuous real time ¹³C urea breath analyser for Helicobacter pylori
pp. 389-394(6)
Authors: Shirin, H.; Kenet, G.; Shevah, O.; Wardi, Y.; Birkenfeld, S.; Shahmurov, M.; Bruck, R.; Niv, Y.; Moss, S. F.; Avni, Y.

Post-treatment diagnostic accuracy of a new enzyme immunoassay to detect Helicobacter pylori in stools
pp. 395-401(7)
Authors: Costa, F.; Mumolo, M. G.; Bellini, M.; Romano, M. R.; Manghetti, M.; Paci, A.; Maltinti, G.; Marchi, S.

One-week ranitidine bismuth citrate-based triple therapy for the eradication of Helicobacter pylori in Hong Kong with high prevalence of metronidazole resistance
pp. 403-409(7)
Authors: Wong, B. C. Y.; Wong, W. M.; Wang, W. H.; Fung, F. M. Y.; Lai, K. C.; Chu, K. M.; Yuen, S. T.; Leung, S. Y.; Hu, W. H. C.; Yuen, M. F.; Lau, G. K. K.; Chan, C. K.; Lam, S. K.

Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate
pp. 411-416(6)
Authors: Fakheri, H.; Malekzadeh, R.; Merat, S.; Khatibian, M.; Fazel, A.; Alizadeh, B. Z.; Massarrat, S.

Five-day proton pump inhibitor-based quadruple therapy regimen is more effective than 7-day triple therapy regimen for Helicobacter pylori infection
pp. 417-421(5)
Authors: Nagahara, A.; Miwa, H.; Yamada, T.; Kurosawa, A.; Ohkura, R.; Sato, N.

Validation of a new immunoblot assay for the diagnosis of Helicobacter pylori in the Asian population
pp. 423-428(6)
Authors: Leung, W. K.; Chow, T. P.; Ng, E. K. W.; Chan, F. K. L.; Chung, S. C. S.; Sung, J. J. Y.